A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanubrutinib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions
Sponsors BeiGene

22 Jan 2025 Status changed from recruiting to active, no longer recruiting.
05 Nov 2024 According to a BeiGene media release, data from a Phase 2 study showed patients with prior intolerance to acalabrutinib were able to safely and effectively switch to BRUKINSA, will be presented, at the 66th ASH Annual Meeting and Exposition in San Diego, Dec 7-10.
12 Dec 2023 Updated Results (As of May 15, 2023, n=27 )presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com